Based on the measurements of operating efficiency obtained from MaxCyte's historical financial statements, MaxCyte is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March. At this time, MaxCyte's Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 21.1 M in 2026, whereas Current Deferred Revenue is likely to drop slightly above 3.7 M in 2026.
The financial analysis of MaxCyte is a critical element in measuring its lifeblood. Investors should not minimize MaxCyte's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Please note, the imprecision that can be found in MaxCyte's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of MaxCyte. Check MaxCyte's Beneish M Score to see the likelihood of MaxCyte's management manipulating its earnings.
MaxCyte Stock Summary
MaxCyte competes with Profound Medical, TriSalus Life, Anteris Technologies, LENSAR, and Owlet. MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. The company was incorporated in 1998 and is headquartered in Rockville, Maryland. Maxcyte operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 84 people.
The reason investors look at the income statement is to determine what MaxCyte's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining MaxCyte's current stock value. Our valuation model uses many indicators to compare MaxCyte value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across MaxCyte competition to find correlations between indicators driving MaxCyte's intrinsic value. More Info.
MaxCyte is considered to be number one stock in return on equity category among its peers. It is regarded fourth in return on asset category among its peers . At this time, MaxCyte's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value MaxCyte by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Most indicators from MaxCyte's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into MaxCyte current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MaxCyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
Today, most investors in MaxCyte Stock are looking for potential investment opportunities by analyzing not only static indicators but also various MaxCyte's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of MaxCyte growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of MaxCyte help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of MaxCyte. We use our internally-developed statistical techniques to arrive at the intrinsic value of MaxCyte based on widely used predictive technical indicators. In general, we focus on analyzing MaxCyte Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build MaxCyte's daily price indicators and compare them against related drivers.
When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.